|OncoCyte Continues to Make Progress Towards Commercialization; Reports First Quarter 2017 Results|
April 28, 2017
|Expects to Report Results of 300 Patient R&D Validation Study on May 22, 2017
Conference Call Scheduled for May 22, 2017 at 4:30pm ET
ALAMEDA, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported its financial results for the quarter ended March 31, 2017. In addition, OncoCyte announced it will conduct an investor call on May 22, 2017 at 4:30pm ET/1:30 pm... |
|Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'|
April 26, 2017
|-57% of AML patients treated with AST-VAC1, including high-risk patients, had prolonged relapse-free survival-
FREMONT, Calif., April 26, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the results from its completed Phase 2 clinical trial of AST-VAC1 are now available online in Cancer, a leading peer-reviewed journal of the American Cancer Society. The study publication ... |
|BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017|
April 26, 2017
|Conference Call and Webcast on Wednesday, May 10, 2017, at 4:30 p.m.
ET / 1:30 p.m. PT
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2017--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that it will release first quarter financial
and operating results on Wednesday, May 10, 2017, after the close of the
U.S. financial markets. The Compa... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|